Intima media thickness of the carotid artery in primary antiphospholipid syndrome: A systematic review and meta-analysis

Tommaso Bucci, Mira Merashli, Pasquale Pignatelli, Daniele Pastori, José Delgado-Alves, Gregory Y.H. Lip, Paul R.J. Ames

Research output: Contribution to journalReview articlepeer-review

Abstract

Background: Primary antiphospholipid syndrome (PAPS) has been associated with an increase in clinical events associated with atherosclerotic vascular disease. Intima media thickness (IMT) of carotid arteries is a surrogate marker of atherosclerotic vascular disease. Objectives: To conduct a systematic review and meta-analysis of studies evaluating IMT and their clinical correlates in PAPS. Methods: Systematic search of EMBASE and PubMed databases from January 2000 to December 2023; we employed random effect meta-analyses for continuous outcomes and Peto's odds ratio for rare events. Results: The meta-analysis included 21 studies (20 case control and 1 cohort) showing that PAPS patients (n = 1103) had thicker IM than controls (n = 832) (p < 0.0001) with wide heterogeneity (I2 = 86.9 %); PAPS patients (n = 782) also had a greater pooled prevalence of carotid plaques than controls (n = 537) (13.1 % vs 2.97 %, p < 0.0001). A sensitivity analysis by meta-regression indicated that mean age, gender, disease duration, lipid profile, blood pressures, smoking and statin use all explained the heterogeneity variance; a sensitivity analysis by subgroups confirmed smoking status and statin use as explanatory variables with the addition of ethnicity. Conclusion: Atherosclerosis of the carotid artery represents a clinical feature of PAPS in relation to the traditional risk factors and to statin use. Minimising the atherogenic risk with statins could reduce the late arterial atherothrombotic risks of PAPS.

Original languageEnglish
Article number103657
JournalAutoimmunity Reviews
Volume23
Issue number11
DOIs
Publication statusPublished - Nov 2024

Keywords

  • atherosclerosis
  • intima media thickness
  • Primary antiphospholipid syndrome

Cite this